Ultragenyx Pharmaceutical (RARE) closed at $16.14 on November 10, 2026, down 1.6% from the previous close, on volume of 2,389,644 shares (30-day average 3,635,583).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Put Spread | 16-Oct-2620 : 27.5 P | 3,964 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Fri, 6-Nov 3:30 AM ET)
Market Chameleon (Wed, 4-Nov 4:04 AM ET)
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
Globe Newswire (Tue, 27-Oct 4:05 PM ET)
Globe Newswire (Wed, 14-Oct 8:30 AM ET)
Globe Newswire (Wed, 7-Oct 8:30 AM ET)
Globe Newswire (Fri, 2-Oct 2:00 AM ET)
PRNewswire (Thu, 24-Sep 5:35 PM ET)
Ultragenyx wins first FDA approval for Sanfilippo Type A with single-dose gene therapy FAYUVI
Market Chameleon (Fri, 18-Sep 3:07 AM ET)
Globe Newswire (Thu, 17-Sep 3:48 PM ET)
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Ultragenyx Pharmaceutical trades on the NASDAQ stock market under the symbol RARE.
As of November 10, 2026, RARE stock price declined to $16.14 with 2,389,644 million shares trading.
RARE has a beta of 2.25, meaning it tends to be more sensitive to market movements. RARE has a correlation of 0.12 to the broad based SPY ETF.
RARE has a market cap of $1.59 billion. This is considered a Small Cap stock.
Last quarter Ultragenyx Pharmaceutical reported $173 million in Revenue and -$1.16 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.33.
In the last 3 years, RARE traded as high as $60.37 and as low as $12.73.
The top ETF exchange traded funds that RARE belongs to (by Net Assets): XBI, VTI, IWM, VB, VBK.
RARE has underperformed the market in the last year with a return of -47.3%, while the SPY ETF gained +12.9%. In the last 3 month period, RARE fell short of the market, returning -37.7%, while SPY returned -2.8%. However, in the most recent 2 weeks RARE has outperformed the stock market by returning +0.4%, while SPY returned -2.0%.
RARE support price is $15.81 and resistance is $17.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RARE shares will trade within this expected range on the day.
